As Il­lu­mi­na dis­ap­points Wall Street, com­peti­tors make their case at JPM

Last Sep­tem­ber, Il­lu­mi­na pledged to de­ci­pher a per­son’s ge­net­ic code for as lit­tle as $200 with its new se­quenc­ing ma­chines, part of a wider push to make ge­net­ic test­ing a rou­tine part of check-ups.

At the JP Mor­gan Health­care Con­fer­ence on Wednes­day, com­peti­tor El­e­ment Bio­sciences said its tech­nol­o­gy could al­so se­quence a genome for $200 – and po­ten­tial­ly with ma­chines that cost less.

“Our goal is to de­moc­ra­tize se­quenc­ing by dri­ving down costs,” said El­e­ment CEO Mol­ly He.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER